Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

This paragraph from ICER pretty much sums up

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Mellowmood77 Member Profile
Member Level 
Followed By 26
Posts 533
Boards Moderated 0
Alias Born 04/30/19
160x600 placeholder
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Manage... GlobeNewswire Inc. - 9/3/2019 6:00:00 AM
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/28/2019 6:00:00 AM
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Choles... GlobeNewswire Inc. - 8/27/2019 6:00:00 AM
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2019 6:34:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2019 6:30:41 AM
Amarin Reports Second Quarter 2019 Financial Results and Operational Update GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares GlobeNewswire Inc. - 7/29/2019 5:17:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2019 4:32:58 PM
Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019 GlobeNewswire Inc. - 7/24/2019 6:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2019 5:01:04 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/18/2019 11:47:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/17/2019 4:38:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 4:02:07 PM
Amarin Announces $400,000,000 Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/17/2019 4:01:00 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 8:15:19 AM
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance GlobeNewswire Inc. - 7/2/2019 6:00:00 AM
Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences GlobeNewswire Inc. - 6/21/2019 1:39:19 PM
Mellowmood77 Member Level  Tuesday, 09/17/19 03:05:22 AM
Re: None
Post # of 220198 
This paragraph from ICER pretty much sums up what the ADCOM should be about:

Regardless of issues of trial design or interpretation, the greatest uncertainty may be in how generalizable the REDUCE-IT results are and therefore what the most appropriate target population will be. As with COMPASS, the patients enrolled in REDUCE-IT were at very high risk of cardiovascular events, as illustrated by a placebo event rate of approximately 4.4% per year over the 4.9-year median duration of follow-up.9 Patients also were on statin therapy, and it is unclear whether icosapent ethyl would be effective in patients not treated with statins. How the benefits of icosapent ethyl translate to an eligible population that is certain to be both broader and at lower risk than the trial population remains to be seen.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist